Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder

Neuropsychopharmacology

Volumn 40, Issue 2, 2015, Pages 463-471

  Savitz, Jonathan ^a,b   Drevets, Wayne C ^a,c   Smith, Chelsey M ^a   Victor, Teresa A ^a   Wurfel, Brent E ^a   Bellgowan, Patrick S F ^a,b   Bodurka, Jerzy ^a,d   Teague, T Kent ^d,e   Dantzer, Robert ^f  

^a LAUREATE INSTITUTE FOR BRAIN RESEARCH   (United States)

^b UNIVERSITY OF TULSA   (United States)

^c JOHNSON AND JOHNSON   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e OKLAHOMA STATE UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYKYNURENINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; KYNURENINE; QUINOLINIC ACID; TRYPTOPHAN; 3-HYDROXYKYNURENINE; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR; KYNURENIC ACID;

ADULT; AMYGDALOID NUCLEUS; ANHEDONIA; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DSM-IV; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAY MATTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MALE; METABOLITE; NEUROPROTECTION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; AMYGDALA; ANALOGS AND DERIVATIVES; BLOOD; METABOLISM; ORGAN SIZE; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; SIGNAL TRANSDUCTION;

ADULT; AMYGDALA; ANHEDONIA; BRAIN-DERIVED NEUROTROPHIC FACTOR; C-REACTIVE PROTEIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMANS; KYNURENIC ACID; KYNURENINE; MALE; ORGAN SIZE; PSYCHIATRIC STATUS RATING SCALES; QUINOLINIC ACID; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION; TRYPTOPHAN;

EID: 84927126178     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.194     Document Type: Article

References (62)

1. Barrientos RM, Frank MG, Hein AM, Higgins EA, Watkins LR, Rudy JW et al (2009). Time course of hippocampal IL-1 beta and memory consolidation impairments in aging rats following peripheral infection. Brain Behav Immun 23: 46-54.
2. Bellac CL, Coimbra RS, Christen S, Leib SL (2006). Pneumococcal meningitis causes accumulation of neurotoxic kynurenine metabolites in brain regions prone to injury. Neurobiol Dis 24: 395-402.
3. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D et al (2003). Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 54: 906-914.
4. Chiappelli J, Pocivavsek A, Nugent KL, Notarangelo FM, Kochunov P, Rowland LM et al (2014). Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. JAMA Psychiatry 71: 761-768.
5. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9: 46-56.
6. Dantzer R, O'Connor JC, Lawson MA, Kelley KW (2011). Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36: 426-436.
7. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al (2010). A meta-analysis of cytokines in major depression. Biol Psychiatry 67: 446-457.
8. Fallarino F, Vacca C, Orabona C, Belladonna ML, Bianchi R, Marshall B et al (2002). Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol 14: 65-68.
9. First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). American Psychiatric Press: Washington, DC.
10. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR (1991). Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56: 2007-2017.
11. Gabbay V, Klein RG, Katz Y, Mendoza S, Guttman LE, Alonso CM et al (2010). The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry 51: 935-943.
12. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T et al (2008). Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 13: 717-728.
13. Gray JD, Milner TA, McEwen BS (2013). Dynamic plasticity: the role of glucocorticoids, brain-derived neurotrophic factor and other trophic factors. Neuroscience 239: 214-227.
14. Haroon E, Raison CL, Miller AH (2012). Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37: 137-162.
15. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001). The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases nonalpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21: 7463-7473.
16. Howren MB, Lamkin DM, Suls J (2009). Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71: 171-186.
17. Johansson AS, Owe-Larsson B, Asp L, Kocki T, Adler M, Hetta J et al (2013). Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. JPsychiatr Res 47: 1815-1823.
18. Kessler M, Terramani T, Lynch G, Baudry M (1989). A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52: 1319-1328.
19. Kim H, Chen L, Lim G, Sung B, Wang S, McCabe MF et al (2012). Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest 122: 2940-2954.
20. Kocki T, Wnuk S, Kloc R, Kocki J, Owe-Larsson B, Urbanska EM (2012). New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio. J Neural Transm 119: 235-243.
21. Koo JW, Duman RS (2008). IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 105: 751-756.
22. Koolschijn PC, van Haren NE, Cahn W, Schnack HG, Janssen J, Klumpers F et al (2010). Hippocampal volume change in schizophrenia. J Clin Psychiatry 71: 737-744.
23. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS (2009). Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp 30: 3719-3735.
24. Kuperberg GR, Broome MR, McGuire PK, David AS, Eddy M, Ozawa F et al (2003). Regionally localized thinning of the cerebral cortex in schizophrenia. Arch Gen Psychiatry 60: 878-888.
25. Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR (2011). Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety-and depression-like behaviours in mice: focus on individual differences. Pharmacol Biochem Behav 98: 161-168.
26. Liu WL, Lin YH, Xiao H, Xing S, Chen H, Chi PD et al (2014). Epstein-Barr virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-kappaB pathways: impairment in T cell functions. J Virol 88: 6660-6671.
27. Maciejak P, Szyndler J, Turzynska D, Sobolewska A, Kolosowska K, Lehner M et al (2013). The kynurenine pathway: a missing piece in the puzzle of valproate action? Neuroscience 234: 135-145.
28. Maes M, Berk M, Goehler L, Song C, Anderson G, Galecki P et al (2012). Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 10: 66.
29. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R (2011). The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 35: 702-721.
30. Maxwell M (1992). Family Interview for Genetic Studies (FIGS): Manual for FIGS. Clinical Neurogenetics Branch, Intramural Research Program, National Institute of Mental Health Bethesda, MD.
31. Miller AH (2013). Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression. Neuropsychopharmacology 38: 1607-1608.
32. Monnerie H, Shashidhara S, Le Roux PD (2003). Effect of excess extracellular glutamate on dendrite growth from cerebral cortical neurons at 3 days in vitro: involvement of NMDA receptors. J Neurosci Res 74: 688-700.
33. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B (2007). Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 98: 143-151.
34. Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpe S et al (2011). Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun 25: 1576-1581.
35. O'Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N et al (2009). Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14: 511-522.
36. Olsson SK, Andersson AS, Linderholm KR, Holtze M, Nilsson-Todd LK, Schwieler L et al (2009). Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int J Neuropsychopharmacol 12: 501-512.
37. Olsson SK, Sellgren C, Engberg G, Landen M, Erhardt S (2012). Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord 14: 719-726.
38. Orabona C, Pallotta MT, Grohmann U (2012). Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol Med 18: 834-842.
39. Pereira AC, Huddleston DE, Brickman AM, Sosunov AA, Hen R, McKhann GM et al (2007). An in vivo correlate of exerciseinduced neurogenesis in the adult dentate gyrus. Proc Natl Acad Sci USA 104: 5638-5643.
40. Perkins MN, Stone TW (1982). An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247: 184-187.
41. Petrik D, Lagace DC, Eisch AJ (2012). The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building? Neuropharmacology 62: 21-34.
42. Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu HQ et al (2010). Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35: 1734-1742.
43. Puccetti P, Grohmann U (2007). IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 7: 817-823.
44. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G et al (2010). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15: 393-403.
45. Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH et al (2002). Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 58: 695-701.
46. Savitz J, Drevets WC (2009). Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev 33: 699-771.
47. Savitz J, Nugent AC, Bogers W, Liu A, Sills R, Luckenbaugh DA et al (2010). Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. Neuroimage 49: 2966-2976.
48. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012). Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13: 465-477.
49. Schwarcz R, Whetsell WO Jr, Mangano RM (1983). Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219: 316-318.
50. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C et al (2008). Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 42: 151-157.
51. Steiner J, Bogerts B, Sarnyai Z, Walter M, Gos T, Bernstein HG et al (2012). Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired bloodbrain barrier integrity. World J Biol Psychiatry 13: 482-492.
52. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z et al (2011). Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 8: 94.
53. Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY et al (2004). Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 56: 640-650.
54. Stone TW, Darlington LG (2002). Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1: 609-620.
55. Vernon AC, Crum WR, Lerch JP, Chege W, Natesan S, Modo M et al (2013). Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugslinking magnetic resonance imaging findings to cellular pathology. Biol Psychiatry 75: 982-990.
56. Vithlani M, Hines RM, Zhong P, Terunuma M, Hines DJ, Revilla-Sanchez R et al (2013). The ability of BDNF to modify neurogenesis and depressive-like behaviors is dependent upon phosphorylation of tyrosine residues 365/367 in the GABA(A)-receptor gamma2 subunit. J Neurosci 33: 15567-15577.
57. Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B et al (2013). NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/ 6J mice. Neuropsychopharmacology 38: 1609-1616.
58. Williamson LL, Bilbo SD (2013). Chemokines and the hippocampus: a new perspective on hippocampal plasticity and vulnerability. Brain Behav Immun 30: 186-194.
59. Winter H, Irle E (2004). Hippocampal volume in adult burn patients with and without posttraumatic stress disorder. Am J Psychiatry 161: 2194-2200.
60. Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE et al (2011). Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 68: 665-674.
61. Yirmiya R, Goshen I (2011). Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 25: 181-213.
62. Zunszain PA, Anacker C, Cattaneo A, Choudhury S, Musaelyan K, Myint AM et al (2012). Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37: 939-949.